Content - SAKK has activated a new trial for patients with kidney cancer

SAKK has activated a new trial for patients with kidney cancer

The SAKK 07/17 trial investigates the treatment of kidney cancer using immunotherapy with nivolumab and ipilimumab.

The aim of the SAKK 07/17 trial is to find out whether combined immunotherapy with nivolumab and ipilimumab in patients with advanced kidney cancer that cannot be treated surgically or has formed secondary tumours is effective and can stop the cancer growing or cause it to recede. We also want to find out which factors determine whether or not a patient responds to the medicines. For this reason we will be taking blood and tissue samples in addition to administering the treatment. These samples are important in finding out why the medication works. Nivolumab and ipilimumab have already been authorized singly for the treatment of kidney cancer. They can activate the immune system and in this way help to fight the cancer. Yet these treatments only work in a small proportion of patients. There is initial evidence that a combination of nivolumab and ipilimumab could have a better effect in more patients. We want to investigate this in more detail in this study. In SAKK 07/17 all patients will be given the same medicinal products. This means that all participants will benefit from a treatment that may be better. The treatment will last up to 2 years, depending on its effect.

All news